1Bast RJ;Feeney M;Lazarus H.Reactivity of a monoclonal antibody with human ovarian carcinoma[J],1981(05).
2Gagnon A;B Ye.Discovery and application of protein biomarkers for ovarian cancer[J],2008(01).
3Jacobs IJ;Menon U.Progress and challenges in screening for early detection of ovarian cancer[J],2004(04).
4Anderson GL;McIntosh M;Wu L.Assessing lead time of selected ovarian cancer biomarkers:a nested case-control study[J],2010(01).
5Zurawski VJ;Orjaseter H;Andersen A.Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia:relevance for early detection of ovarian cancer[J],1988(05).
6Woolas RP;Xu FJ;Jacobs IJ.Elevation of multiple serum markers in patients with stage I ovarian cancer[J],1993(21).
7Bon GG;Kenemans P;Verstraeten R.Serum tumor marker immunoassays in gynecologic oncology:establishment of reference values[J],1996(01).
8Alagoz T;Buller RE;Berman M.What is a normal CA125 level[J],1994(01).
9Skates SJ;Menon U;MacDonald N.Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women,2003(10 Suppl).
10Partridge E;Barnes MN.Results from four rounds of ovarian cancer screening in a randomized trial,2009(04).
2Rustin GJ,Quinn M,Thigpen T,et al.New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)[J].J Natl Cancer Inst,2004,96:487-488.
3Bristow RE,Tomacruz RS,Armstrong DK,et al.Survival effect of maximal cyto-reductive surgery for advanced ovarian carcinoma during the platinum era:ametaan-alysis[J].J Clin Oncol,2002,20 (5):1248-1259.
4Griffiths CT,Fuller AF.Intensive surgical and chemotherapcutic management of advanced ovarian cancer[J].Surg Clin North Am,1978,58(1):131-142.
5Hegazy MA,Hegazi RA,Elshafei MA,et al.Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma[J].World J Surg Oncol,2005,31(3):57-65.
8Li J,Dowdy S, Tipton T,et al. HE4 as a biom 盯 ker for ovarI and endo-metrial cancer management[J]. Expen Rev Mol Diagn, 2009,9:555-566.
9Anderson GL, Mclntosh M, Wu L, et al. Assessing lead time of selected ovarian cancer biomarkers:a nested case-control study [J]. J Natl Cancer Inst,2010,102(1) :26-38.
10Wang K,Lu G,Jeffery E,et a. LMonitoring gene erpression pro- file change in ovarian carcinomas using cDNA microarray of genes involved in ovarian carcinogenesis[J]. Cancer Res, 2000, 60:5007-5011.
